Transrectal Fusion Biopsy
Leonard S. Marks, MD provides a comprehensive analysis of transrectal fusion biopsy, improving the accuracy of prostate cancer detection.
Read More
Los Angeles
The Evolution of the Role of Radical Prostatectomy in Prostate Cancer
Dr. Leonard S. Marks provides a comprehensive analysis of the evolving role of radical prostatectomy in prostate cancer treatment. He traces the historical development of this surgical procedure, highlighting key advancements and the shifting paradigms that have shaped its current status.
Nerve-sparing techniques have revolutionized the procedure by reducing the rates of postoperative erectile dysfunction and urinary incontinence. Dr. Marks details how these innovations, along with enhanced imaging techniques and robotic-assisted surgery, have refined the precision and efficacy of radical prostatectomy, making it a viable option for a broader range of patients.
Dr. Marks also addresses the role of radical prostatectomy in managing high-risk and advanced prostate cancer. He explores the emerging evidence supporting its use in combination with other treatments, such as androgen deprivation therapy and radiation, to enhance overall survival rates and reduce disease recurrence.
Read More
MRI Fusion Focal Therapy
Leonard S. Marks, MD examines the use of MRI fusion to enhance the precision and effectiveness of focal therapy in treating prostate cancer.
Read More
PET Imaging for Selection of Focal Therapy Candidates
Jeremie Calais, MD, MSc, discusses the game-changing prostate cancer imaging agent PSMA. He reviews recent studies and how PSMA PET imaging can be used to inform strategies in prostate cancer treatment.
Read More
How to Integrate PSMA PET Findings Into Treatment Algorithms
Jérémie Calais, MD, MSc, Associate Professor of Nuclear Medicine and Theranostics in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Director of the UCLA Theranostics Program, and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division discusses how to integrate prostate-specific membrane antigen (PSMA) positron emission tomography (PET) findings into treatment algorithms. Dr. Calais explains that PSMA PET results in new staging categories, has predictive value, and has value in response assessment. He emphasizes that inclusion criteria of randomized phase-3 trials must include PSMA PET staging/screening/selection for PSMA PET to be integrated into treatment algorithms.
Read More